Embla Medical hf (OCSE:EMBLA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:EMBLA Embla Medical hf OCSE:EMBLA
91 GF Score
Price kr26.50
GF Value kr34.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OCSE:EMBLA
91GF Score
Embla Medical hf OCSE:EMBLA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr26.50 is trading 23.6% below its estimated GF Value™ of kr34.68. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr34.68 vs. price of kr26.50 (23.6% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Other Exchanges 0FIW:UK5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score

Get the complete analysis for OCSE:EMBLA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.50
Price
kr34.68
GF Value